Ionis and Akcea launch Phase III trial to treat polyneuropathy

Ionis and Akcea have launched a Phase III clinical trial of AKCEA-TTR-L to treat polyneuropathy in patients with hereditary TTR (hATTR) amyloidosis. Credit: Ed Uthman via Flickr.